REGN Stock Sinks As Regeneron’s Eylea Sales Suffer| Investor’s Business Daily

Biotech giant Regeneron Pharmaceuticals (REGN) said Monday that sales of its linchpin Eylea drug in the final quarter of 2022 were hurt by a shift to an off-label competitor. REGN stock plunged on the...

WHO Backs Merck’s Antiviral Pill For High-Risk Covid Patients But Finds Regeneron’s Antibody Cocktail ‘Ineffective’ Against Omicron

Topline The World Health Organization has recommended Merck’s molnupiravir to treat high-risk Covid patients, the agency announced Thursday, the first oral antiviral it has endorsed though availabilit...